Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

To assess whether immunization attenuates nicotinic stimulation of the brain and elucidate brain and behavioural responses during exposure to smoking cues and a working memory task.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

Subjects were tested on two occasions, once after a nicotine challenge and once after a placebo challenge, and were asked to refrain from smoking 10 hours before testing.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and parallel-group study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.

Randomized, placebo-controlled parallel-group, repeated-measures design.

Reaction-times and accuracies were recorded during an n-back task.

Moreover, regional blood oxygenated level-dependent (BOLD) response was measured during this task and during smoking cue exposure.

What Was Measured

PubMed files the paper under topics including Brain, Cues, Magnetic Resonance Imaging, Memory, Short-Term, Netherlands, Nicotinic Agonists and Psychomotor Performance.

Author keywords: fMRI, immunization, nicotine, nicotine vaccine, smoking cues and tobacco addiction.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and parallel-group study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Addiction (Abingdon, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.